This week: Empiric antibiotic choices for community acquired pnuemonia and clindamycin versus trimethoprim-sulfamethoxazole for skin and soft tissue infections.
Fahad and Amol want you to understand the following:
1. A large, high quality RCT showed that there was no significant difference between an empiric treatment strategy of beta-lactam vs beta-lactam plus macrolide vs respiratory fluoroquinolone for the treatment of community-acquired pneumonia requiring hospitalization in a non-ICU setting.
2. A high quality RCT showed that there was no significant difference between clindamycin and TMP-SMX, with respect to either efficacy or side-effect profile, for the treatment of uncomplicated skin infections in regions with endemic Methicillin-Resistant Staphylococcus Aureus.
Continuing Medical Education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
The papers
DF Postma et al. Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. N Engl J Med. 2015 Apr 2;372(14):1312-23. (PubMed).
LG Miller et al. Clindamycin versus Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Infections. N Engl J Med. 2015 Mar 19;372(12):1093-103. (PubMed).
Good stuff
Anglo-Saxon remedy kills hospital superbug MRSA. Clare Wilson. New Scientist. 30 Mar 2015.
Genetically Determined Height and Coronary Artery Disease.
